Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region.
Over-expression of the c-myc gene is widely implicated in the genesis of lymphoid neoplasia, including tumours of the T-cell lineage. To study the effects of deregulated c-myc expression on T-cell development and oncogenesis, we sought to generate a transgenic mouse model in which c-myc expression was targeted specifically to the T-cell lineage. A plasmid construct containing a dominant control region (DCR) from the human CD2 locus linked 5' to the human c-myc gene was used to generate 2 lines of transgenic mice. Both strains developed thymic lymphoma at low frequency, but thymic development and peripheral T-cell numbers were otherwise apparently normal. Low tumour penetrance was consistent with the observed lack of stable CD2-myc transgene mRNA in tissues of healthy transgenic mice. In contrast, transgene RNA was detected in all malignant tumours as well as in early lymphomatous lesions. RNase protection analyses confirmed these findings and showed that the PI human c-myc promoter was active in all neoplastic tissues but not in the thymus or other tissues of healthy transgenic mice. Despite the low spontaneous tumour incidence, the presence of the transgene markedly and uniformly accelerated the onset of tumours after neonatal infection with Moloney murine leukaemia virus. All tumours were rearranged for T-cell receptor beta-chain genes and were of T-cell origin from their surface phenotype (Thy-1+, CD3+, CD4+/-, CD8+, sIg-). Virus-accelerated tumours contained clonal integrations of Moloney murine leukaemia virus, suggesting that proviral insertional mutagenesis may have played a role in tumour development. Analysis of several candidate myc-cooperating genes failed to reveal any rearrangements apart from a low frequency involving proviral insertion at the pim-1 locus. The CD2-myc mouse should therefore be a valuable system in screening for novel myc-collaborating genes involved in T-cell lymphoma.
Stewart
M
M
Beatson Institute for Cancer Research, Cancer Research Campaign Beatson Laboratories, Bearsden, Glasgow, UK.
Cameron
E
E
Campbell
M
M
McFarlane
R
R
Toth
S
S
Lang
K
K
Onions
D
D
Neil
J C
JC
D000818:Animals; D001483:Base Sequence; D005260:Female; D015870:Gene Expression / Q000235:genetics*; D015321:Gene Rearrangement / Q000235:genetics; D015329:Gene Rearrangement, T-Lymphocyte / Q000235:genetics; D005799:Genes, Dominant / Q000235:genetics*; D005803:Genes, Immunoglobulin / Q000235:genetics; D016259:Genes, myc / Q000235:genetics*; D008040:Genetic Linkage / Q000235:genetics*; D006801:Humans; D007942:Leukemia, Experimental / Q000235:genetics / Q000382:microbiology; D015458:Leukemia, T-Cell / Q000235:genetics* / Q000382:microbiology; D016399:Lymphoma, T-Cell / Q000235:genetics* / Q000382:microbiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D008979:Moloney murine leukemia virus; D010641:Phenotype; D011401:Promoter Regions, Genetic / Q000235:genetics; D013601:T-Lymphocytes / Q000502:physiology*; D013950:Thymus Gland / Q000502:physiology; D013953:Thymus Neoplasms / Q000235:genetics